Transaction DateRecipientSharesTypePriceValue
23rd September 2020Partners L P/Il Bvf7,201Open or private purchase$18.20$131,056.76
23rd September 2020Partners L P/Il Bvf9,888Open or private purchase$18.20$179,959.62
22nd September 2020Partners L P/Il Bvf32Open or private purchase$3.80$121.56
22nd September 2020Partners L P/Il Bvf4,991Open or private purchase$18.45$92,062.49
22nd September 2020Partners L P/Il Bvf6,960Open or private purchase$18.45$128,382.07
21st September 2020Partners L P/Il Bvf10,069Open or private purchase$18.39$185,119.57
21st September 2020Partners L P/Il Bvf12,259Open or private purchase$18.39$225,382.94
18th September 2020Venture Investments, Llc Alexandria38,461Open or private purchase$13.00$499,993.00
18th September 2020Venture Investments, Llc Alexandria1,268,795Conversion of derivative$0.00
15th September 2020Partners L P/Il Bvf10,258Open or private purchase$11.75$120,531.50
Ideaya Biosciences
Ideaya Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


IDEA Biosciences, Inc. develops cancer therapeutics. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


Ticker: IDYA
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1676725
Employees: 47
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals